Last reviewed · How we verify
NCT02947035
Molecular Testing to Direct Extent of Initial Thyroid Surgery
Phase 2 trial testing Thyroid lobectomy in Thyroid Cancer in 100 participants. Completed in 1 June 2023.
1 June 2023
Quick facts
| Lead sponsor | University of Pittsburgh |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 1 February 2017 |
| Primary completion | 1 June 2023 |
| Estimated completion | 1 June 2023 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Thyroid lobectomy
- Total thyroidectomy with CCND
Conditions studied
- Thyroid Cancer — all drugs for Thyroid Cancer →
Sponsor
University of Pittsburgh
Who can join
18 and older, any sex, with Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The research study consists of the participant agreeing to 1) the use of preoperative molecular testing (ThyroSeq) to guide extent of initial surgery and 2) the prospective collection of medical record data related to treatment of thyroid cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02947035
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Thyroid lobectomy
Trials testing the same drug.
- NCT06583057 — Multicenter Comparison of Thermal Ablation Versus Thyroid Lobectomy for Subcapsular Papillary Thyroid Microcarcinoma · completed
Other recruiting trials for Thyroid Cancer
Currently open trials in the same condition.
- NCT07428057 — Postoperative Hypocalcemia After Thyroidectomy · recruiting
- NCT07370675 — Active Surveillance for Bethesda IV Thyroid Nodules · NA · recruiting
- NCT07389512 — Pharmaceutical Management in Targeted Radioligand Therapy · recruiting
- NCT07438847 — 177Lu-CTR-FAPI for the Treatment of Thyroid Cancer · Phase 1 · recruiting
- NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting
Other University of Pittsburgh trials
Trials by the same sponsor.
- NCT05601206 — Collaborative Care Intervention for Cancer Patients and Their Family Caregivers -LITE · NA · not yet recruiting
- NCT06652815 — Cognition, Metacognition, and Stigma in Patients With Suicidal Ideation · not yet recruiting
- NCT06474286 — Prucalopride for Cognitive Functioning in Schizophrenia · NA · not yet recruiting
- NCT06488469 — Behavioural Problems and Cognition in Children With Hypoglycemia Unawareness in Type-1 Diabetes Mellitus · NA · not yet recruiting
- NCT06652802 — Effectiveness of Nurse-Conducted Brief Intervention (NCBI) Supplemented With Mobile for Preventing Alcohol Use Disorders · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02947035 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pittsburgh
- Last refreshed: 14 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02947035.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing